Telangiectasia hemorrágica hereditaria: tratamiento farmacológico / Pharmacological treatment of hereditary haemorrhagic telangiectasia
Rev. méd. Chile
; 137(5): 695-700, mayo 2009.
Article
en Es
| LILACS
| ID: lil-521874
Biblioteca responsable:
BR1.1
ABSTRACT
Hereditary hemorrhagic telangiectasia (HHT) of Rendu-Osler-Weber disease is a multi system vascular dysplasia characterized by the presence of multiple telangiectasias, mainly affecting mucosal tissue and arterial-venous connections. It commonly affects lungs, liver and central nervous system. Bleeding is the most common symptom and its treatment can be surgical or pharmacological. We herein review the systemic therapy that attempts to minimize bleeding as well as blood transfusion therapy. Blood therapy and fibrinolytic treatment especially aminocaproic acid and tranexamic acid are discussed. Danazol, hormone therapy and other less common drugs used in the treatment of HHT are also reviewed.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Telangiectasia Hemorrágica Hereditaria
Límite:
Humans
Idioma:
Es
Revista:
Rev. méd. Chile
Asunto de la revista:
MEDICINA
Año:
2009
Tipo del documento:
Article
País de afiliación:
España